IP Library Granted Patent US 8,892,365
Granted Patent B2
US 8,892,365 · App. 13/767,207 · Granted Nov 18, 2014

Optimized probe selection method

Inventors: Todd Richmond (Madison, WI); Jason Norton (Madison, WI); Emile F. Nuwaysir (Madison, WI); Roland Green (Madison, WI); Kate Nuwaysir (Madison, WI)
Assignee: Ventana Medical Systems, Inc.
C12Q1/6837C12Q1/6811G06F19/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,892,365
App. No.
13/767,207
Granted
Nov 18, 2014
Kind
B2
Abstract

The present invention provides methods for optimizing oligonucleotide hybridization probes for use in basic and clinical research. Specifically, the invention involves hybridizing serially diluted genomic sample to the oligonucleotide probes on the array, such that a signal intensity is produced for each of the probes; computationally identifying optimized probes which exhibit signal intensities that correspond to the serial dilutions of genomic sample and are reproducibly strong relative to non-optimized probes.

Claims (13)

1. A method for selecting optimized oligonucleotide probes for use in a hybridization-based assay from an original oligonucleotide probe set, the method comprising the steps of:

a) providing the original oligonucleotide probe set on a first and second hybridization array;

b) providing serial dilutions of a genomic sample, wherein the genomic sample is labeled;

c) hybridizing a first dilution of the labeled and serially diluted genomic sample to the first hybridization array, d) measuring a signal intensity produced for each of the probes;

e) hybridizing a second dilution of the labeled and serially diluted genomic sample to the second hybridization array;

f) measuring a second signal intensity produced for each of the probes;

g) computationally generating weighted regression data from the signal intensity produced for each of the probes;

h) entering the regression data into a database; and

i) querying the database to select optimized probes which exhibit signal intensities that correspond to the serial dilutions of genomic sample, are reproducible, and are strong relative to other probes in the original probe set.

2. The method of claim 1 , wherein the oligonucleotide probes are DNA or RNA.

3. The method of claim 1 , wherein the hybridization-based assays are selected from the group consisting of microarray-based assays, bead-based assays, genotyping assays, and RNAi assays.

4. The method of claim 1 , wherein the hybridization-based assays is a microarray-based assay.

5. The method of claim 4 , wherein the microarray is synthesized by maskless array synthesis.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2014
From: ROCHE NIMBLEGEN, INC.
To: VENTANA MEDICAL SYSTEMS, INC.
Reel/Frame 033315/0537 →
CHANGE OF NAME Recorded Jul 15, 2014
From: NIMBLEGEN SYSTEMS, INC.
To: ROCHE NIMBLEGEN, INC.
Reel/Frame 033329/0166 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2014
From: RICHMOND, TODD; NORTON, JASON; NUWAYSIR, EMILE F.; GREEN, ROLAND; NUWAYSIR, KATE
To: NIMBLEGEN SYSTEMS, INC.
Reel/Frame 033307/0178 →
Continuity (4)
Continuation 12963076 · Dec 8, 2010
Continuation 11346927 · Feb 3, 2006
Provisional Application 60650265 · Feb 4, 2005
Related Publication 20140031244A1 · Jan 30, 2014